Physician profile
Robert G Thum
NPI 1265492102
$1,612.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $298.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $343.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $301.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $172.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.61 | 2019-2020 | |
| Mylan Specialty L.P. | $115.30 | 2019-2020 | |
| Philips North America LLC | $107.96 | 2019 | |
| Insmed, INC. | $90.00 | 2019-2020 | |
| Circassia INC. | $71.26 | 2019-2020 | |
| Electromed, INC. | $65.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $64.17 | 2019-2020 | |
| Grifols USA, LLC | $44.11 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $29.89 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.51 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $25.25 | 2019-2020 | |
| Genzyme Corporation | $15.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Thum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.